FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078677052> ?p ?o ?g. }

• W2078677052 endingPage "2975" @default.
• W2078677052 startingPage "2968" @default.
• W2078677052 abstract "Loss of body mass, or wasting, is a major cause of morbidity and a contributor to mortality in human immunodeficiency virus-1 (HIV-1) infection. Dietary supplements and appetite adjuvants have had limited effectiveness in treating this condition. GH and insulin-like growth factor I (IGF-I) have been shown to be anabolic in many catabolic conditions, and limited data suggest similar efficacy in HIV wasting. In addition, it appears that GH and IGF-I may have complementary anabolic effects with opposing glucoregulatory effects. We report results from a 12-week randomized, placebo-controlled trial of combination recombinant human GH (rhGH; Nutropin; 0.34 mg, sc, twice daily) and rhIGF-I (5.0 mg, sc, twice daily) in individuals with HIV wasting and without active opportunistic infection, cancer, or gastrointestinal disease. A total of 142 subjects (140 males and 2 females) were randomized using a 2:1, double blind treatment scheme and assigned to receive either active treatment or placebo injections. Eighty subjects completed the 12-week protocol. Nutritional intake and demographic and clinical characteristics did not differ between the groups at any study time point. At 3 weeks, the treatment group had a significantly larger weight increase (P = 0.0003), but this difference was not observed at any later time point. Similarly, fat-free mass, calculated from skinfold measurements, increased transiently in the treatment group at 6 weeks (P = 0.002). No significant differences in isokinetic muscle strength or endurance testing or in quality of life were observed between the groups. Resting heart rate was significantly higher in the treatment group at each time point post-baseline. GH and IGF-binding protein-3 levels did not change; however, IGF-I levels were higher in the treatment group at 6 and 12 weeks. There were no significant between-group differences in any of the measured biochemical or immunological parameters. rhGH plus rhIGF-I treatment was associated with an increased incidence of peripheral edema and other side-effects, possibly related to fluid retention. We conclude that the combination of rhIGF-I and low dose rhGH used in this study had no significant anabolic effect in HIV wasting." @default.
• W2078677052 created "2016-06-24" @default.
• W2078677052 creator A5004962376 @default.
• W2078677052 creator A5007264662 @default.
• W2078677052 creator A5015238904 @default.
• W2078677052 creator A5042364388 @default.
• W2078677052 creator A5050631860 @default.
• W2078677052 creator A5051764883 @default.
• W2078677052 creator A5052425400 @default.
• W2078677052 creator A5057836454 @default.
• W2078677052 creator A5086345751 @default.
• W2078677052 creator A5087186163 @default.
• W2078677052 creator A5091652325 @default.
• W2078677052 date "1996-08-01" @default.
• W2078677052 modified "2023-10-13" @default.
• W2078677052 title "A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection." @default.
• W2078677052 cites W1969435041 @default.
• W2078677052 cites W1984178591 @default.
• W2078677052 cites W2033476492 @default.
• W2078677052 cites W2061566400 @default.
• W2078677052 cites W2063663267 @default.
• W2078677052 cites W2072508608 @default.
• W2078677052 cites W2121094822 @default.
• W2078677052 cites W292398390 @default.
• W2078677052 doi "https://doi.org/10.1210/jcem.81.8.8768860" @default.
• W2078677052 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8768860" @default.
• W2078677052 hasPublicationYear "1996" @default.
• W2078677052 type Work @default.
• W2078677052 sameAs 2078677052 @default.
• W2078677052 citedByCount "23" @default.
• W2078677052 countsByYear W20786770522017 @default.
• W2078677052 crossrefType "journal-article" @default.
• W2078677052 hasAuthorship W2078677052A5004962376 @default.
• W2078677052 hasAuthorship W2078677052A5007264662 @default.
• W2078677052 hasAuthorship W2078677052A5015238904 @default.
• W2078677052 hasAuthorship W2078677052A5042364388 @default.
• W2078677052 hasAuthorship W2078677052A5050631860 @default.
• W2078677052 hasAuthorship W2078677052A5051764883 @default.
• W2078677052 hasAuthorship W2078677052A5052425400 @default.
• W2078677052 hasAuthorship W2078677052A5057836454 @default.
• W2078677052 hasAuthorship W2078677052A5086345751 @default.
• W2078677052 hasAuthorship W2078677052A5087186163 @default.
• W2078677052 hasAuthorship W2078677052A5091652325 @default.
• W2078677052 hasBestOaLocation W20786770521 @default.
• W2078677052 hasConcept C1008401 @default.
• W2078677052 hasConcept C121608353 @default.
• W2078677052 hasConcept C126322002 @default.
• W2078677052 hasConcept C134018914 @default.
• W2078677052 hasConcept C142724271 @default.
• W2078677052 hasConcept C168563851 @default.
• W2078677052 hasConcept C170493617 @default.
• W2078677052 hasConcept C204787440 @default.
• W2078677052 hasConcept C27081682 @default.
• W2078677052 hasConcept C2775960820 @default.
• W2078677052 hasConcept C2777704314 @default.
• W2078677052 hasConcept C2779764123 @default.
• W2078677052 hasConcept C2780689927 @default.
• W2078677052 hasConcept C2911126609 @default.
• W2078677052 hasConcept C511355011 @default.
• W2078677052 hasConcept C544821477 @default.
• W2078677052 hasConcept C71924100 @default.
• W2078677052 hasConcept C90924648 @default.
• W2078677052 hasConceptScore W2078677052C1008401 @default.
• W2078677052 hasConceptScore W2078677052C121608353 @default.
• W2078677052 hasConceptScore W2078677052C126322002 @default.
• W2078677052 hasConceptScore W2078677052C134018914 @default.
• W2078677052 hasConceptScore W2078677052C142724271 @default.
• W2078677052 hasConceptScore W2078677052C168563851 @default.
• W2078677052 hasConceptScore W2078677052C170493617 @default.
• W2078677052 hasConceptScore W2078677052C204787440 @default.
• W2078677052 hasConceptScore W2078677052C27081682 @default.
• W2078677052 hasConceptScore W2078677052C2775960820 @default.
• W2078677052 hasConceptScore W2078677052C2777704314 @default.
• W2078677052 hasConceptScore W2078677052C2779764123 @default.
• W2078677052 hasConceptScore W2078677052C2780689927 @default.
• W2078677052 hasConceptScore W2078677052C2911126609 @default.
• W2078677052 hasConceptScore W2078677052C511355011 @default.
• W2078677052 hasConceptScore W2078677052C544821477 @default.
• W2078677052 hasConceptScore W2078677052C71924100 @default.
• W2078677052 hasConceptScore W2078677052C90924648 @default.
• W2078677052 hasIssue "8" @default.
• W2078677052 hasLocation W20786770521 @default.
• W2078677052 hasLocation W20786770522 @default.
• W2078677052 hasOpenAccess W2078677052 @default.
• W2078677052 hasPrimaryLocation W20786770521 @default.
• W2078677052 hasRelatedWork W167251473 @default.
• W2078677052 hasRelatedWork W1981296195 @default.
• W2078677052 hasRelatedWork W1989980876 @default.
• W2078677052 hasRelatedWork W2031654731 @default.
• W2078677052 hasRelatedWork W2040023294 @default.
• W2078677052 hasRelatedWork W2105755717 @default.
• W2078677052 hasRelatedWork W2111343721 @default.
• W2078677052 hasRelatedWork W2314840099 @default.
• W2078677052 hasRelatedWork W3008148827 @default.
• W2078677052 hasRelatedWork W4214670365 @default.
• W2078677052 hasVolume "81" @default.
• W2078677052 isParatext "false" @default.
• W2078677052 isRetracted "false" @default.

• next